Isofol announces approval of another clinical patent for arfolitixorin in the United States. The patent is focused on the dose regimen used in the ongoing clinical AGENT study and expires in 2038. We expect the patent, together with the already approved applications and applications under review, to give arfolitixorin a strong IP protection when the drug candidate reaches market. Today’s news does not affect our valuation of Isofol.